Medical Drug Therapy

SciClone will cut 7 jobs in restructuring after canceling cancer drug trial SciClone Pharmaceuticals Inc. on Wednesday said it will cut 17 percent of its U.S. work force — or about 7 jobs — as part of a corporate restructuring. The restructuring ...

Scientists have recently made developments in the medical drug therapy field concerning spinal cord injuries. The main improvement has been finding a target-these molecules, chondroitin sulfate proteoglycans, bind to the surface of neurons. The CSPGs are released by cells in spinal cord ...

Hospira profit climbs on sales of generic chemotherapy treatment and other specialty drugs Hospira Inc. said Tuesday its profit jumped 42 percent in the third quarter due to rising sales of specialty drugs, primarily a generic chemotherapy treatment. The drug and medication ...

GAO finds FDA unwilling to pull drugs off the market, even when their benefits are unclear The Food and Drug Administration has allowed drugs for cancer and other diseases to stay on the market even when follow-up studies showed they didn't extend ...

Supreme Court Justice Ruth Bader Ginsburg, who had cancer surgery earlier this year, was kept at a hospital overnight after she became drowsy and fell from her seat aboard an airplane. Court officials blamed a reaction to medicine. It was the second ...

In this Tuesday, Oct. 13, 2009 photo, Pharmacist Les Logan holds up common cold medicines at Rinderer's drug store containing pseudoephedrine, in Union, Mo. The small eastern Missouri town is now forcing consumers to get a doctor's prescription for the common over-the-counter ...

CHICAGO (Reuters) - Women whose breasts became tender after taking hormone replacement therapy had nearly twice the risk of developing breast cancer than women whose breasts did not become tender on the drugs, U.S. researchers said on Monday. They said breast tenderness ...

Onyx Pharmaceuticals Inc. said Monday it will buy cancer drug developer Proteolix Inc. in a deal that could be worth as much as $851 million. Onyx shares advanced $1.36, or 5.1 percent, to close at $28.26. Onyx will pay $276 million upfront ...

WASHINGTON (Reuters) - The U.S. Food and Drug Administration's review staff expressed doubts that GlaxoSmithKline Plc's experimental kidney cancer drug Votrient should be approved given concerns about liver injury, documents released on Thursday said. Votrient, also known by its chemical name pazopanib, ...

BERLIN (Reuters) - Cancer patients whose tumors are targeted with heat treatment as well as chemotherapy are more likely to stay alive and cancer-free for longer than those who receive only chemotherapy, researchers said on Tuesday. The finding suggests it may be ...